Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice
Clinical trial NCT06907082 · COMPLETED
Trial details
- NCT number
- NCT06907082
- Sponsor
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- Status
- COMPLETED
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-28
- Primary completion
- 2024-03-14
- Enrollment
- 106
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.